XKRX220100
Market cap232mUSD
Dec 27, Last price
15,470.00KRW
1D
1.11%
1Q
-37.11%
Jan 2017
155.92%
IPO
118.40%
Name
FutureChem Co Ltd
Chart & Performance
P/E
—
P/S
24.47
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
15.81%
Rev. gr., 5y
19.91%
Revenues
13.97b
+11.09%
Net income
-6.71b
L-51.94%
CFO
-3.72b
L-51.12%
Profile
FutureChem Co.,Ltd produces and sells radiopharmaceuticals in Korea. The company offers PDVUE, a positron emission tomography (PET) radiopharmaceutical diagnostic medicine for Parkinson's disease; Alzavue, a diagnostic medicine for Aalzheimer's disease; and [18F]FDG, a PET radiopharmaceutical for the treatment of cancer. Its products in pipeline include 18F-FC303, a diagnostic PET radiopharmaceuticals for the treatment of prostate cancer; 177Lu-FC705 for the treatment of prostate cancer; 18F-FMT for the treatment of brain tumor; 18F-FC505, for the treatment of atherosclerotic plaque; and 18F-FC211, for the treatment of Alzheimer's disease. FutureChem Co.,Ltd was founded in 1999 and is headquartered in Seoul, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 13,968,016 11.09% | 12,573,624 6.39% | 11,818,367 7.31% | |||||
Cost of revenue | 17,412,429 | 20,969,728 | 15,536,523 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (3,444,412) | (8,396,104) | (3,718,156) | |||||
NOPBT Margin | ||||||||
Operating Taxes | 11,284 | 3,930 | (43,927) | |||||
Tax Rate | ||||||||
NOPAT | (3,455,696) | (8,400,034) | (3,674,229) | |||||
Net income | (6,708,943) -51.94% | (13,959,368) 308.22% | (3,419,589) -85.20% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 31,054,250 | |||||||
BB yield | -16.95% | |||||||
| Debt | ||||||||
Debt current | 1,062,724 | 10,089,903 | 7,355,639 | |||||
Long-term debt | 3,682,519 | 3,845,262 | 11,294,532 | |||||
Deferred revenue | 36,968 | 59,809 | 83,992 | |||||
Other long-term liabilities | 2,621,586 | 2,668,888 | 2,592,293 | |||||
Net debt | (25,097,793) | (33,168,231) | (17,800,694) | |||||
| Cash flow | ||||||||
Cash from operating activities | (3,720,059) | (7,609,985) | (2,947,156) | |||||
CAPEX | (2,422,063) | (3,957,718) | (9,981,996) | |||||
Cash from investing activities | 19,662,691 | (15,906,345) | 4,302,066 | |||||
Cash from financing activities | (10,521,416) | 23,195,246 | (1,656,498) | |||||
FCF | (5,778,461) | (6,897,014) | (12,773,480) | |||||
| Balance | ||||||||
Cash | 25,968,387 | 41,074,202 | 32,967,879 | |||||
Long term investments | 3,874,649 | 6,029,193 | 3,482,986 | |||||
Excess cash | 29,144,636 | 46,474,715 | 35,859,946 | |||||
Stockholders' equity | (56,898,524) | (50,302,243) | (40,752,031) | |||||
Invested Capital | 127,153,970 | 135,326,717 | 112,170,965 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 22,097 | 19,070 | 18,492 | |||||
Price | 10,550.00 9.78% | 9,610.00 -31.73% | 14,076.92 -25.15% | |||||
Market cap | 233,122,590 27.21% | 183,260,009 -29.60% | 260,308,416 8.65% | |||||
EV | 208,169,831 | 150,239,655 | 242,707,109 | |||||
EBITDA | 2,186,692 | (3,829,378) | 811,025 | |||||
EV/EBITDA | 95.20 | 299.26 | ||||||
Interest | 478,141 | 1,356,893 | 1,321,908 | |||||
Interest/NOPBT | ||||||||